Corteria Pharmaceuticals team is growing with the arrival of two very valuable members: Eléonore Jouanny who will be in charge of the CMC activities of our assets and Stephane Durant des Aulnois who is our new CFO and will manage the business development.
Eléonore has 15 years of experience in international pharmaceutical global project management. She is a Pharmacist and holds a PhD in Pharmacotechny and Biopharmacy from Paris XI University. She started her career at Biogaran as a project manager in industrial transfers and production, leading 20+ tech-transfers and launches. She then joined Substipharm where she successfully managed more than 30 development plans from R&D to scale-up and tech-transfer steps. Facilitating drug access to patients has always been of personal importance to Eléonore, leading her to join Corteria.
Prior to joining Corteria, Stéphane Durant des Aulnois served as Chief Financial Officer & Head of Alliances and Business development at Lysogene, a ph3 gene therapy company listed on Euronext, where he successfully led capital raising activities and closed the acquisition of two assets. Previously, Stéphane Durant des Aulnois spent nine years at Ipsen, first as Vice-President Head of Investor Relations for the Group, then as CFO of Ipsen Iberia, in charge of financial, procurement and supply chain activities. Earlier in his career, he worked in Private Equity at LaSalle Investment management, at Calyon Americas and at Exane BNP Paribas as a sell-side research Analyst. He holds a master’s degree (MSc) in Accounting and Finance from the London School of Economics (LSE) and in Management from Paris Dauphine University. He also holds an Executive Leadership degree from Harvard Business School.”